{
    "clinical_study": {
        "@rank": "141307", 
        "arm_group": [
            {
                "arm_group_label": "LY2928057 (No ESA)", 
                "arm_group_type": "Experimental", 
                "description": "Multiple doses of LY2928057 administered intravenously (IV) either once every 2 weeks (Q2W) or once per week (QW) for 6 weeks.  Participants discontinued their personal physician-prescribed erythropoiesis stimulating agent (ESA) before treatment."
            }, 
            {
                "arm_group_label": "LY2928057 (Reduced ESA)", 
                "arm_group_type": "Experimental", 
                "description": "Multiple doses of LY2928057 administered IV either Q2W or QW for 6 weeks.  Participants reduced their personal physician-prescribed ESA dose before treatment."
            }, 
            {
                "arm_group_label": "Placebo (No ESA)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Multiple doses of placebo administered IV either Q2W or QW for 6 weeks.  Participants discontinued their personal physician-prescribed ESA dose before treatment."
            }, 
            {
                "arm_group_label": "Placebo (Reduced ESA)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Multiple doses of placebo administered IV either Q2W or QW for 6 weeks. Participants reduced their personal physician-prescribed ESA dose before treatment."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the safety of LY2928057 and how LY2928057 affects hemoglobin in\n      hemodialysis participants.  This study will involve multiple doses of LY2928057 given during\n      a 6 week period either after a participant discontinues or reduces treatment to stimulate\n      red blood cells.  The study will last about 20 weeks for each participant."
        }, 
        "brief_title": "A Study of LY2928057 in Hemodialysis Participants", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Renal Insufficiency, Chronic", 
            "Kidney Disease, Chronic"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Chronic Disease", 
                "Kidney Diseases", 
                "Renal Insufficiency", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participants with end-stage renal disease (ESRD) who have been receiving adequate\n             maintenance hemodialysis (3 times weekly) for at least 12 weeks prior to screening\n             (meaning participants Kt/V is greater than 1.1 [K equals dialyzer clearance of urea,\n             t equals dialysis duration time, V equals volume of distribution of urea, which is\n             approximately equal to the participants total body water]) and who are willing to\n             stop or reduce their stable erythropoiesis stimulating agent (ESA) dose for\n             approximately 2 weeks prior to the first administration of the study drug\n\n          -  Have a hemoglobin value greater than or equal to 9.0 grams per deciLiter (g/dL) and\n             less than or equal to 12 g/dL at screening and greater than or equal to 9 g/dL and\n             less than or equal to 11.5 g/dL, prior to dialysis after ESAs have been stopped or\n             reduced for 1 to 3 weeks (that is, before randomization to LY2928057 or placebo). The\n             difference between the hemoglobin values at the above 2 time points must be less than\n             or equal to 1.5 grams\n\n          -  Have a body mass index (BMI) of 18.5 to 45 kilograms per square meter (kg/m^2)\n             inclusive at screening\n\n          -  Have a transferrin saturation (TSat) greater than or equality to 15 percent and\n             ferritin greater than 40 nanograms per  milliliter (ng/mL) at screening\n\n        Exclusion Criteria:\n\n          -  Any cause of anemia other than renal disease\n\n          -  A history of hyporesponsiveness to ESA"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01991483", 
            "org_study_id": "15268", 
            "secondary_id": "I5M-MC-FABC"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LY2928057 (No ESA)", 
                    "LY2928057 (Reduced ESA)"
                ], 
                "description": "Administered intravenously", 
                "intervention_name": "LY2928057", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Placebo (No ESA)", 
                    "Placebo (Reduced ESA)"
                ], 
                "description": "Administered intravenously", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hematinics"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 21, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Lakewood", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80228"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55404"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2928057 in Hemodialysis Patients", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to study completion (approximately 20 weeks)"
            }, 
            {
                "measure": "Change From Baseline in Hemoglobin at 6 Week Endpoint", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 6 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01991483"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacodynamics (PD):  Maximum Change in Hemoglobin (Hb)", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 6 weeks"
            }, 
            {
                "measure": "Pharmacodynamics (PD):  Maximum Change in Serum Iron (Fe) Concentrations", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 6 weeks"
            }, 
            {
                "measure": "Pharmacodynamics (PD):  Maximum Change in Transferrin Saturation (TSat)", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 6 weeks"
            }, 
            {
                "measure": "Pharmacodynamics (PD):  Maximum Change in Concentration of Hemoglobin in Reticulocytes (CHr)", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 6 weeks"
            }, 
            {
                "measure": "Pharmacodynamics (PD):  Maximum Change in Reticulocyte Count", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 6 weeks"
            }, 
            {
                "measure": "Pharmacodynamics (PD):  Maximum Change in Red Blood Cell (RBC) Count", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 6 weeks"
            }, 
            {
                "measure": "Pharmacodynamics (PD):  Maximum Change in Mean Corpuscular Volume (MCV)", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 6 weeks"
            }, 
            {
                "measure": "Pharmacodynamics (PD):  Maximum Change in Mean Corpuscular Hemoglobin (MCH)", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 6 weeks"
            }, 
            {
                "measure": "Pharmacodynamics (PD):  Maximum Change in Mean Corpuscular Hemoglobin Concentration (MCHC)", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 6 weeks"
            }, 
            {
                "measure": "Pharmacodynamics (PD):  Maximum Change in Ferritin", 
                "safety_issue": "No", 
                "time_frame": "Baseline through 6 weeks"
            }, 
            {
                "measure": "Pharmacokinetics:  Maximum Concentration (Cmax) of LY2928057", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to 84 days post last dose"
            }, 
            {
                "measure": "Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2928057", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to 84 days post last dose"
            }, 
            {
                "measure": "Number of Participants Who Develop Anti-LY2928057 Antibodies", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose up to 84 days post last dose"
            }, 
            {
                "measure": "Ratio of AUC During Dialysis Versus After Dialysis", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose through 14 days post-dose"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}